Abstract:Background TNF-α-blocking therapy is a successful treatment strategy for rheumatoid arthritis (RA), but is associated with reduced resistance to tuberculosis. We have developed a vaccine against mouse TNF-α (TNF-KLH) which protects mice from collagen-induced arthritis (CIA) and collagen-antibodies-induced arthritis (CAIA). We aimed at modelizing the infectious risk/benefit ratio of TNF-α neutralisation by comparing different strategies of TNF-α targeting in experimental Mycobacterium tuberculosis infection. Materials and methods 4 groups (TNF-KLH, etanercept, KLH, PBS) of 10 C57BL/6 mice were compared with TNF deficient mice (TNF -/-). Vaccines were emulsified in IFA before i.m. administration (days −44, –31, −17 and −4). Other treatments were given from D0. All groups were infected at day 0 by 104 cfu of Mycobacterium tuberculosis (H37Rv virulent strain). Mouse groups were divided in two arms: one was euthanized 28 days post-infection, the lasting mice were euthanized 56 days post-infection. Bacterial burden was evaluated in lungs. Cellular infiltration was studied by immunohistological analysis. Results A sustained anti-TNF-α antibody production was obtained in vaccinated mice. At day 28 of Mycobacteria infection, bacterial burden, organ weights, neutrophils and B cells infiltration were similar between TNF-KLH, KLH and PBS groups. At this time point, histological analysis showed higher surface of granuloma in liver of etanercept and TNF-/- groups than TNF-KLH group. At day 56 post infection, etanercept group presented higher surface of liver and lung granuloma than TNF-KLH and KLH groups. These observations were in accordance with a progression of the disease in etanercept group, whereas such effect was not retrieved in TNF-KLH and immunocompetent groups (KLH, PBS). Conclusion Our results indicate that anti-TNF-α vaccination could protect mice from inflammatory arthritis without deeply altering host immunity against infection, suggesting the existence of two distinct pathophysiologic thresholds for TNF-α inhibition, one for arthritis improvement, the other for infection facilitation. These thresholds might be dependend on the TNF inhibition strategy.

Protective effect of T cell receptor-heat shock protein 70 DNA vaccines on collagen-induced arthritis

Protective Effects of Overexpression TCR Vbeta5.2-HSP70 and TCR Vbeta8.2-HSP70 Against Collagen-Induced Arthritis in Rats.

[Experiment Treatment of Collagen-Induced Arthritis in Rats with Recombinant Plasmid Containing Vasoactive Intestinal Peptide Gene].

Vaccination with A Dna Vaccine Based on Human Psca and Hsp70 Adjuvant Enhances the Antigen-Specific Cd8(+) T-Cell Response and Inhibits the Psca(+) Tumors Growth in Mice

Immunoregulatory Roles of T Cells Vaccine in Collagen Induced Arthritis

Therapeutic Effect of Tolerogenic Antigen Presenting Cell on Collagen-Induced Arthritis in Rats

HLA-DRB1 binding CⅡ263-272 peptide inhibits collagen-induced arthritis

Inhibition of Collagen-Induced Arthritis by HLA-DRβ1 Specific Non-T Cell Binding Peptide

Protective Effects of OPG-HSP70 Fusion Protein on CIA Rats

Protection of Rats from Adjuvant Arthritis by Immunization with Naked Dna Encoding for Mycobacterial Heat Shock Protein 65

Treatment with Recombinant Hsp72 Suppresses Collagen-Induced Arthritis in Mice

Therapeutic role of a vaccine targeting RANKL and TNF-α on collagen-induced arthritis.

Therapeutic effects of TACI-Ig on collagen-induced arthritis by regulating T and B lymphocytes function in DBA/1 mice.

Co-Expression of Il-18 Binding Protein and Il-4 Regulates Th1/Th2 Cytokine Response in Murine Collagen-Induced Arthritis

Anti-Inflammatory Effects of Recombinant Human PDCD5 (rhPDCD5) in a Rat Collagen-Induced Model of Arthritis

[Effect of Multiple Amino Acid Substitutions of Collagen II 263-272 on Collagen-Induced Arthritis].

Anti-T-Cell Receptor Antibody Treatment of Rats with Established Autologous Collagen-Induced Arthritis - Suppression of Arthritis Without Reduction of Anti-Type-Ii Collagen Autoantibody Levels

T Cell Vaccination Inhibits Th1/Th17/Tfh Frequencies and Production of Autoantibodies in Collagen-Induced Arthritis

Therapeutic Vaccination of Active Arthritis with a Glycosylated Collagen Type II Peptide in Complex with MHC Class II Molecules

06.11 Anti-tnf-α Vaccination Protects from Experimental Arthritis Without Negatively Affecting Resistance to Mycobacterium Tuberculosis Infection

Altered Collagen Ii 263-272 Peptide Immunization Induces Inhibition of Collagen-Induced Arthritis Through A Shift Toward Th2-Type Response